Caribou Biosciences – a company focused on genome-editing – has announced follow-up data from the dose escalation element of its ongoing ANTLER phase 1 trial.
This new data set includes all 16 patients treated in dose escalation with the CB-010 candidate – an allogeneic anti-CD19 CAR-T cell therapy being researched among patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
All of the individuals had aggressive r/r B-NHL and had received two or more prior lines of chemoimmunotherapy or were primary refractory patients.
